Novo Nordisk

Market Access

From BIO 2025: Kyle Touchstone, director of Economic Development Raleigh and Laura Rowley, director of life sciences development for NCBiotech.

News

The UK is studying cases of pancreatitis in people taking GLP-1 drugs for weight loss or type 2 diabetes to see if genetics may make them vulnerable.

News

The alliance between Novo Nordisk and telehealth firm Hims & Hers for the distribution of GLP-1 agonist weight-loss therapies has ended in acrimony.

News

Roche has positive data with its follow-up to haemophilia A blockbuster Hemlibra, but a rival drug from Novo Nordisk is looming.

News

Novo Nordisk's phase 3 data for CagriSema at ADA raises questions about how weight loss data in obesity trials are interpreted.

News

Reports say Novo Nordisk may have inadvertently let generics of its GLP-1 drug semaglutide for diabetes and obesity launch in Canada early next year.